Zevra sinks on CHMP opinion for arimoclomol in NPC

AI Briefing

• – Zevra's stock price dropped after CHMP's negative opinion on arimoclomol in Non-Progressive Paraplegia.
• – CHMP recommends "not to recommend" arimoclomol for treatment of Non-Progressive Paraplegia.
• – Zevra's shares fell by 15% following the CHMP's decision on arimoclomol.